## CRSP: CRISPR Therapeutics AG - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.2% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($50.28)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies**
- Source: Finviz | 20251223T103500 | Bullish | Relevance: 100%
- CRISPR Therapeutics stock saw a 3.7% increase following positive early data from studies on its zugocaptagene geleucel (zugo-cel) therapy candidate. This therapy is being evaluated for autoimmune diseases, showing deep B-cell depletion and meaningful clinical improvement, and for B-cell malignancies, where it demonstrated strong activity and a high complete response rate. The company also announced a collaboration with Eli Lilly to evaluate zugo-cel in combination with Jaypirca for aggressive B-cell lymphomas.

**2. CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112â„¢) in Autoimmune Diseases and Hematologic Malignancies**
- Source: GlobeNewswire | 20251222T131013 | Bullish | Relevance: 100%
- CRISPR Therapeutics announced encouraging preliminary data for zugocaptagene geleucel (zugo-cel) in autoimmune diseases, showing deep B-cell depletion and significant clinical improvement, including remission in a SLE patient. The company also reported positive single-agent activity in relapsed or refractory large B-cell lymphoma, with a high overall response rate. Additionally, a new Phase 1 basket trial for zugo-cel has been initiated in ITP and wAIHA, and a collaboration with Lilly to evaluate zugo-cel with pirtobrutinib in aggressive B-cell lymphomas was established.

**3. Citizens Jmp Reaffirms Market Outperform Rating for CRISPR Therapeutics (NASDAQ:CRSP)**
- Source: MarketBeat | 20251223T140921 | Somewhat-Bullish | Relevance: 100%
- Citizens Jmp has reiterated a "Market Outperform" rating for CRISPR Therapeutics (NASDAQ:CRSP), setting an $86 price target, which suggests a 48.5% upside from the current share price. Despite this positive rating, the company remains unprofitable, and insiders, including the CEO, have recently sold significant stakes in the company. The consensus among 22 analysts is a "Hold" rating with an average target price of $68.35.

**4. CRISPR Therapeutics (NASDAQ:CRSP) Receives Buy Rating from Needham & Company LLC**
- Source: MarketBeat | 20251223T140920 | Somewhat-Bullish | Relevance: 100%
- Needham & Company LLC reiterated a "Buy" rating for CRISPR Therapeutics (NASDAQ:CRSP) with an $80 price target, implying a 38% upside despite the company's deeply unprofitable status and missed revenue expectations. Insider selling, including a significant reduction in position by CEO Samarth Kulkarni, was noted. Multiple other analysts have also weighed in on CRSP, resulting in an average "Hold" rating across the board.

**5. CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer**
- Source: Benzinga | 20251222T181013 | Bullish | Relevance: 100%
- CRISPR Therapeutics provided an update on zugocaptagene geleucel (zugo-cel), an investigational allogeneic CAR T therapy. The therapy showed a 90% overall response rate and 70% complete response rate in patients with relapsed/refractory large B-cell lymphoma (LBCL), with encouraging preliminary data also seen in autoimmune rheumatologic diseases. The company is collaborating with Eli Lilly and Co. to further develop zugo-cel in aggressive B-cell lymphomas.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-23 | Needham | $80 | $80 | 0% |
| 2025-12-23 | Citizens | $86 | $86 | 0% |
| 2025-11-26 | Chardan Capital | $74 | $82 | -10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-23 | Needham | reit | Buy |
| 2025-12-23 | Citizens | reit | Market Outperform |
| 2025-11-26 | Chardan Capital | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 5 ($3.81M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- ARK Investment Manag: 10.3% (-3.9%)
- Blackrock Inc.: 7.4% (+16.2%)
- Capital Internationa: 5.9% (+1.0%)
- Orbis Allan Gray Ltd: 5.2% (+80.2%)
- State Street Corpora: 4.2% (+22.5%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. High short interest (26.4%, 8.9 days to cover): squeeze risk or crowded bearish bet.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (16.2x), low leverage (D/E 0.17). Revenue growth strong at 1916% YoY. Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $5.4B |
| Beta | 1.73 |
| 52W Range | $30.04 - $78.48 |
| Short Interest | 26.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.21 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 stable at -1.2% (minimal 5-day change). Below STRENGTH zone by 4.2pp (needs >3.0% for momentum thesis). RSI neutral at 51. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.24% (CS: 46) | Neutral |
| RSI_14 | 50.6 | Neutral |
| MACD Histogram | 0.31 | Bullish |
| vs SMA20 | 1.014x | Above |
| vs SMA50 | 0.966x | Below |
| vs SMA200 | 1.102x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $56.46
- **Stop Loss:** $50.28 (10.9% risk)
- **Target:** $62.64 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 194
- **Position Value:** $10,953.24
- **Portfolio %:** 10.95%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.29 | $-1.17 | +9.2% |
| 2025Q2 | $-1.40 | $-1.29 | +7.8% |
| 2025Q1 | $-1.28 | $-1.58 | -23.8% |
| 2024Q4 | $-1.19 | $-0.44 | +62.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*